Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
Authors:
- Laura G EstévezLELaura G Estévez
- Ana Suarez-GauthierASAna Suarez-Gauthier
- Elena GarcíaEGElena García
- Cristina MiróCMCristina Miró
- Isabel CalvoICIsabel Calvo
- María Fernández-AbadMFMaría Fernández-Abad
- Mercedes HerreroMHMercedes Herrero
- Manuel MarcosMMManuel Marcos
- Cristina MárquezCMCristina Márquez
- Fernando Lopez RíosFRFernando Lopez Ríos
- Sofía PereaSPSofía Perea
- Manuel HidalgoMHManuel Hidalgo
Open Access
- 4 September 2014
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 16 (4) , R76
Abstract
Introduction: Human epidermal growth factor receptor 2 (HER2) amplification is frequent in ductal carcinoma in situ (DCIS) of the breast and is associated with poorly differentiated tumors and adverse prognosis features. This study aimed to determine the molecular effects of the HER2 inhibitor lapatinib in patients with HER2 positive DCIS. Methods: Patients with HER2 positive DCIS received 1,500 mg daily of lapatinib for four consecutive weeks prior to surgical resection. Magnetic resonance imaging (MRI) was used to determine changes in tumor volume. The molecular effects of lapatinib on HER2 signaling (PI3K/AKT and RAS/MAPK pathways), cell proliferation (Ki67 and p27) and apoptosis (TUNEL) were determined in pre and post-lapatinib treatment samples. Results: A total of 20 patients were included. Lapatinib was well tolerated with only minor and transient side effects. The agent effectively modulated HER2 signaling decreasing significantly pHER2 and pERK1 expression, together with a decrease in tumor size evaluated by MRI. There was no evidence of changes in Ki67. Conclusions: Four weeks of neoadjuvant lapatinib in patients with HER2-positive DCIS resulted in inhibition of HER2 and RAS/MAPK signaling pathway. Trial registration: 2008-004492-21 (Registered June 25th 2008).Keywords
This publication has 35 references indexed in Scilit:
- Targeting the HER/EGFR/ErbB Family to Prevent Breast CancerCancer Prevention Research, 2011
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinaseProceedings of the National Academy of Sciences of the United States of America, 2011
- Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast CancersJournal of Clinical Oncology, 2011
- Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancerBreast Cancer Research, 2010
- New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted TherapyAmerican Journal of Roentgenology, 2010
- Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breastCancer, 2010
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- LapatinibNature Reviews Drug Discovery, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast CancersCancer Research, 2006